Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1647 • ACR Convergence 2021
Interaction Effect of Systemic Inflammation and Dietary Protein Intake on Resting Energy Expenditure in Individuals with RA
Beatriz Hanaoka¹, Jing Zhao¹, Kristen Heitman¹, Fahad Khan¹, Guy Brock¹, Jeff Volek¹, Wael Jarjour¹ and Barbara Gower², ¹Ohio State University, Columbus, OH, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: In rheumatoid cachexia (RC), high resting energy expenditure (REE) has been associated with loss of muscle mass driven by proinflammatory cytokines. The objectives of…
Abstract Number: 1665 • ACR Convergence 2021
Physical Activity Moderates Inflammatory Gene Expression in Rheumatoid Arthritis
Sarah Patterson¹, Shenghuan Sun², Dmitry Rychkov², Alexandra Tsitsiklis², Paula Hayakawa Serpa², Patricia Katz², Charles Langelier² and Marina Sirota², ¹University of California San Francisco, Pacifica, CA, ²University of California San Francisco, San Francisco, CA
Background/Purpose: Prior studies show an independent association between greater physical activity and lower inflammatory markers among adults in the general population, but the impact of…
Abstract Number: 1681 • ACR Convergence 2021
ATI-450, an Investigational MK2 Inhibitor, Is Well Tolerated and Demonstrated Clinical Activity in Patients with Mod/severe RA: A 12-week Phase 2a, Randomized, Investigator/patient-blind Study Investigating the Safety, Tolerability, PK and PD of ATI-450 + MTX vs PBO + MTX in MTX IR Patients
Alan Kivitz¹, Joe Monahan², David Burt³, Marco Cardillo³, Heidi Hope² and David Gordon³, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Aclaris Therapeutics, St Louis, MO, ³Aclaris Therapeutics, Wayne, PA
Background/Purpose: p38 inhibition has been a focus of research in RA but efficacy in clinical studies was underwhelming, possibly because a large number of pro…
Abstract Number: 1697 • ACR Convergence 2021
Clinical Outcomes up to Week 48 of Filgotinib Treatment in an Ongoing Long-term Extension Trial of RA Patients with Inadequate Response to MTX Initially Treated with Filgotinib or Adalimumab During the Phase 3 Parent Trial
Bernard Combe¹, Yoshiya Tanaka², Paul Emery³, Alena Pechonkina⁴, Albert Kuo⁴, Qi Gong⁴, Katrien Van Beneden⁵, Vijay Rajendran⁶ and Hendrik Schulze-Koops⁷, ¹CHU Montpellier Montpellier University, Montpellier, France, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos, NV, Mechelen, Belgium, ⁶Galapagos NV, Mechelen, Belgium, ⁷Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany
Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in Europe and Japan. We assessed…
Abstract Number: 1889 • ACR Convergence 2021
Arthritogenic T Cells Harbor a Transcriptional Program of T Cell Activation and a Repertoire Pruned by Endogenous Superantigen
JUDITH F ASHOURI, Elizabeth McCarthy, Steven Yu, Noah Perlmutter, Charles Lin, Chun Jimmie Yu and Arthur Weiss, University of California San Francisco, San Francisco, CA
Background/Purpose: It is widely accepted that activation of specific CD4 T cells through their TCRs by self-antigen (Ag) is necessary for rheumatoid arthritis (RA) onset.…
Abstract Number: 1941 • ACR Convergence 2021
The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Christina Charles-Schoeman¹, Roy Fleischmann², Eduardo Mysler³, Maria Greenwald⁴, Cunshan Wang⁵, All-shine Chen⁵, Carol A Connell⁵, John C Woolcott⁶, Sujatha Menon⁵, Yan Chen⁷, Kristen Lee⁷ and Zoltan Szekanecz⁸, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: ORAL Surveillance (NCT02092467) was a randomized, open-label, non-inferiority, Phase 3b/4 study that assessed the relative risk of major adverse cardiovascular (CV) events (MACE) and…
Abstract Number: 0007 • ACR Convergence 2021
Divergent Reactivities of Rheumatoid Factors and Anti-Modified Protein Antibodies Converge on IgG Epitopes
Aisha Mergaert¹, Zihao Zheng¹, Michael Denny¹, Maya Amjadi¹, Janna Bashar¹, Michael Newton¹, Vivianne Malmström², Caroline Grönwall², Sara McCoy¹ and Miriam Shelef¹, ¹University of Wisconsin, Madison, WI, ²Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) patients often develop rheumatoid factors (RFs), antibodies that bind IgG Fc, and anti-modified protein antibodies (AMPAs), multi-reactive autoantibodies that commonly bind…
Abstract Number: 0028 • ACR Convergence 2021
Evolution of Anti-modified Protein Antibody Responses Can Be Driven by Consecutive Exposure to Different Post-translational Modifications
Mikhail Volkov, Arieke Kampstra, Karin van Schie, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Besides anti-citrullinated protein antibodies (ACPA), rheumatoid arthritis patients (RA) often display autoantibody reactivities against other post-translationally modified (PTM) proteins, more specifically carbamylated and acetylated…
Abstract Number: 0044 • ACR Convergence 2021
Autoantibodies Against Malondialdehyde-modifications Promote Osteoclast Development by Reprogramming Cellular Metabolism
Koji Sakuraba¹, Akilan Krishnamurthy¹, Alexandra Circiumaru², Jitong Sun¹, Vijay Joshua¹, Heidi Wähämaa¹, Marianne Engström¹, Meng Sun¹, Xiaowei Zheng¹, Cheng Xu¹, khaled amara¹, Vivianne Malmström¹, Sergiu Catrina¹, Caroline Grönwall¹, Anca Catrina¹ and Bence Réthi¹, ¹Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Malondialdehyde (MDA) is a highly reactive compound generated during lipid-peroxidation in conditions associated with oxidative stress. MDA can irreversibly modify proteins (e.g. lysine, arginine…
Abstract Number: 0155 • ACR Convergence 2021
The Additional Value of MRI in Diagnosis of Rheumatoid Arthritis in Undifferentiated Arthritis Patients
Nikolet den Hollander¹, Marloes Verstappen¹, Navkiran Sidhu¹, Elise van Mulligen², Monique Reijnierse¹ and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Identifying patients that will develop rheumatoid arthritis (RA) among those presenting with undifferentiated arthritis (UA) remains a clinical dilemma. According to EULAR recommendations magnetic…
Abstract Number: 0237 • ACR Convergence 2021
Self-perceived General Health at Start of Anti-TNF Therapy Predicts Therapeutic Response in Patients with Rheumatoid Arthritis: Analysis from the Czech Biologics Registry ATTRA
Jakub Zavada¹ and Lucie Nekvindova², ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institut biostatistiky a analýz, spin-off společnost Masarykovy univerzity, Brno, Brno, Czech Republic
Background/Purpose: SF-36 and its components, as well as other PROs have been shown to predict various disease outcomes. We hypothesized that positive responses to questions…
Abstract Number: 0284 • ACR Convergence 2021
Risk Factors for Dementia in Patients with Incident Rheumatoid Arthritis: A Population-based Cohort Study
Elena Myasoedova¹, Michelle Mielke¹, Cassondra Hulshizer¹, John Davis¹, Vijay Ramanan¹, Maria Vassilaki¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Growing evidence from observational studies suggests that patients with rheumatoid arthritis (RA) are at increased risk for cognitive impairment and dementia. Longitudinal population-based studies…
Abstract Number: 0458 • ACR Convergence 2021
Single Cell Profiling Reveals a Wnt-mediated Transcriptional Gradient That Drives Inflammation in Rheumatoid Arthritis Synovial Fibroblast Pathology
Alisa Mueller¹, Angela Zou¹, Emily Taylor², Triin Major², David Gardner³, Adam Croft⁴, Roche Fibroblast Network Consortium⁵, Andrew Filer², Christopher Buckley⁶, Kevin Wei¹, Ilya Korsunsky¹, Soumya Raychaudhuri¹ and Michael Brenner⁷, ¹Brigham and Women's Hospital, Boston, MA, ²University of Birmingham, Birmingham, United Kingdom, ³University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom, ⁴University of Birmingham, Halesowen, United Kingdom, ⁵Roche Innovation Center Basel, Basel, Switzerland, ⁶University of Oxford, Oxford, United Kingdom, ⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: Synovial fibroblasts are key inflammatory aggressors in rheumatoid arthritis (RA) that mediate cartilage and bone destruction, yet therapies directly targeting these cells are lacking.…
Abstract Number: 0563 • ACR Convergence 2021
Validating the FRAX Score in a US Population-Based Study of Patients with Rheumatoid Arthritis
Madeline Peterson¹, Cynthia Crowson², Elena Myasoedova¹, Shreyasee Amin¹, John Davis¹, Sara Achenbach¹, Sundeep Kholsa¹ and Elizabeth Atkinson¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: The FRAX tool, launched by the World Health Organization Collaborating Centre at the University of Sheffield in 2008 (https://www.sheffield.ac.uk/FRAX/), is widely used to quickly…
Abstract Number: 0586 • ACR Convergence 2021
Recommended Fiber Intake, but Not Overall Dietary Quality, Is Associated with Reduced Risk of Rheumatoid Arthritis – Results from a Nested Case-control Study
Rebecka Bäcklund¹, Isabel Drake¹, Emily Sonestedt², Jan-Åke Nilsson¹, Ulf Bergström¹ and Carl Turesson³, ¹Lund University, Malmö, Sweden, ²Lund University, Lund, Sweden, ³Lund University, Malm, Sweden
Background/Purpose: Diet has received attention as a factor possibly contributing to development of rheumatoid arthritis (RA). The aim of this study was to investigate the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].